AIM ImmunoTech Inc.
AIM
$0.25
-$0.01-3.42%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.50% | -53.33% | -25.71% | -50.00% | -60.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.50% | -53.33% | -25.71% | -50.00% | -60.00% |
| Cost of Revenue | -60.00% | 471.43% | 750.00% | 25.00% | 25.00% |
| Gross Profit | 200.00% | -150.00% | -255.56% | -64.29% | -81.25% |
| SG&A Expenses | -29.78% | -55.20% | -41.60% | -42.61% | -32.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.16% | -49.61% | -45.34% | -28.66% | -37.05% |
| Operating Income | 38.49% | 49.58% | 45.49% | 28.37% | 36.89% |
| Income Before Tax | 18.41% | 30.03% | 11.24% | -52.18% | 36.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.41% | 30.03% | 11.24% | -52.18% | 36.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.41% | 30.03% | 11.24% | -52.18% | 36.31% |
| EBIT | 38.49% | 49.58% | 45.49% | 28.37% | 36.89% |
| EBITDA | 38.70% | 49.77% | 45.93% | 28.68% | 37.26% |
| EPS Basic | 86.81% | 84.51% | 75.55% | -5.90% | 55.16% |
| Normalized Basic EPS | 86.91% | 84.01% | 56.15% | -10.69% | 54.11% |
| EPS Diluted | 86.81% | 84.51% | 75.55% | -5.90% | 55.16% |
| Normalized Diluted EPS | 86.91% | 84.01% | 56.15% | -10.69% | 54.11% |
| Average Basic Shares Outstanding | 518.71% | 351.78% | 262.98% | 43.69% | 42.05% |
| Average Diluted Shares Outstanding | 518.71% | 351.78% | 262.98% | 43.69% | 42.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |